Enclomiphene peptide is also known as:
- Enclomiphene citrate
- Androxal
- RMI-16289
- Enclomid
- DSIP-11
It is a nonsteroidal selective estrogen receptor modulator (SERM) that is being investigated for the treatment of male hypogonadism and other conditions associated with low testosterone levels. It is a synthetic peptide that is derived from the compound clomiphene citrate.
Enclomiphene peptide works by blocking the effects of estrogen on the hypothalamus and pituitary gland. This leads to an increase in the production of gonadotropin-releasing hormone (GnRH), which in turn stimulates the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH are hormones that are essential for testosterone production in the testes.
Enclomiphene peptide is also thought to work by directly stimulating the testes to produce more testosterone. This is thought to be due to the fact that enclomiphene peptide can bind to androgen receptors in the testes. Androgen receptors are the receptors that testosterone binds to in order to exert its effects.
Other names for enclomiphene peptide
Enclomiphene peptide is also sometimes referred to as:
- DSIP-derived SERM
- SERM-11
- Gonadotropin-releasing hormone agonist
- Testosterone booster
Enclomiphene peptide is a promising new drug for the treatment of male hypogonadism and other conditions associated with low testosterone levels. It is well-tolerated and has few side effects. More research is needed to confirm its long-term safety and efficacy, but it has the potential to revolutionize the treatment of male hypogonadism.
It is important to note that enclomiphene peptide is still under investigation and is not yet approved by the FDA for the treatment of any condition.
